{"id":"ticagrelor-90","_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ticagrelor 90","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:40:15.806083+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:40:20.879232+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ticagrelor 90","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:40:21.391513+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purinergic receptor P2Y12 negative allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:40:22.944571+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL398435/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:40:22.611328+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:38:42.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:40:24.131888+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT05149560","phase":"PHASE2","title":"Ticagrelor Monotherapy After Stenting","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-12-14","conditions":"Acute Myocardial Infarction","enrollment":200},{"nctId":"NCT07480629","phase":"","title":"The 10-Year Extended Follow-up of the DACAB Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2026-03-15","conditions":"Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass","enrollment":500},{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT07257198","phase":"PHASE3","title":"Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-03-03","conditions":"NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial Infarction","enrollment":2570},{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT07444164","phase":"PHASE1","title":"Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-01-13","conditions":"Healthy","enrollment":24},{"nctId":"NCT07438886","phase":"PHASE1","title":"Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Advenchen Laboratories Nanjing Ltd.","startDate":"2026-03-02","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT06543082","phase":"PHASE4","title":"MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-08-05","conditions":"Acute Coronary Syndrome","enrollment":490},{"nctId":"NCT06691191","phase":"PHASE4","title":"Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-01-08","conditions":"Coronary Artery Disease","enrollment":48},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT06316570","phase":"PHASE3","title":"Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-04-03","conditions":"Ischemic Stroke, Acute","enrollment":1382},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT06853535","phase":"PHASE3","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2025-05-23","conditions":"Acute Ischemic Stroke, Clopidogrel Resistance","enrollment":5138},{"nctId":"NCT03783351","phase":"NA","title":"Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2019-05-27","conditions":"Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents","enrollment":4009},{"nctId":"NCT05997693","phase":"PHASE3","title":"One-Month DAPT in CABG Patients","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-08-15","conditions":"Chronic Coronary Disease","enrollment":700},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT02505399","phase":"PHASE4","title":"TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2015-11","conditions":"Atherosclerosis","enrollment":180},{"nctId":"NCT06714526","phase":"NA","title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-07","conditions":"Intracranial Atherosclerosis","enrollment":100},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":"Acute Myocardial Infarction","enrollment":2312},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":"ST Elevation Myocardial Infarction, No-Reflow Phenomenon","enrollment":60},{"nctId":"NCT06591377","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-10","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03869268","phase":"PHASE4","title":"The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2019-04-24","conditions":"Acute Coronary Syndrome","enrollment":72},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03560310","phase":"PHASE4","title":"Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2018-06-29","conditions":"Acute Coronary Syndrome","enrollment":2201},{"nctId":"NCT06981390","phase":"NA","title":"Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG","status":"RECRUITING","sponsor":"Kexiang Liu, MD","startDate":"2025-02-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein","enrollment":300},{"nctId":"NCT06318481","phase":"PHASE3","title":"TADCLOT- a Double Blind Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-02-19","conditions":"Stent Thrombosis, Myocardial Infarction, Acute","enrollment":2200},{"nctId":"NCT04360720","phase":"PHASE3","title":"Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-10-15","conditions":"Acute Coronary Syndrome","enrollment":3410},{"nctId":"NCT03357874","phase":"PHASE3","title":"TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-10-28","conditions":"Acute Coronary Syndrome","enrollment":259},{"nctId":"NCT03971500","phase":"NA","title":"1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-08-20","conditions":"Coronary Artery Disease","enrollment":3710},{"nctId":"NCT06509893","phase":"PHASE4","title":"Ticagrelore Alone Post PCI","status":"RECRUITING","sponsor":"Shiraz University of Medical Sciences","startDate":"2024-08-01","conditions":"Coronary Artery Disease","enrollment":5400},{"nctId":"NCT06653348","phase":"PHASE2, PHASE3","title":"Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke","status":"RECRUITING","sponsor":"Mazandaran University of Medical Sciences","startDate":"2024-04-01","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":100},{"nctId":"NCT06554821","phase":"PHASE1","title":"A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-05","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT05767723","phase":"PHASE4","title":"Platelet Sub-study of the Neomindset Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-02-06","conditions":"Acute Coronary Syndrome","enrollment":48},{"nctId":"NCT03551964","phase":"PHASE4","title":"Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2018-08-01","conditions":"Acute Myocardial Infarction, Cardiogenic Shock","enrollment":605},{"nctId":"NCT04484259","phase":"PHASE4","title":"Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":105},{"nctId":"NCT06826144","phase":"NA","title":"Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02-20","conditions":"Unruptured Intracranial Aneurysm, Infarction Cerebral","enrollment":84},{"nctId":"NCT06759272","phase":"PHASE4","title":"Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","status":"NOT_YET_RECRUITING","sponsor":"Nur Hafizah Annezah binti Utuh","startDate":"2025-02","conditions":"Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD","enrollment":120},{"nctId":"NCT06756945","phase":"PHASE4","title":"Low-dose Evaluation of Aspirin After STEMI Patients With PCI: A Multicenter, Double-blind, Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-01","conditions":"ST-elevation Myocardial Infarction (STEMI)","enrollment":3612},{"nctId":"NCT04948749","phase":"NA","title":"Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-02","conditions":"ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent","enrollment":792},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT05476081","phase":"","title":"A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2021-02-03","conditions":"Ischemic Stroke, TIA","enrollment":2239},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":"Vertebral Artery Stenosis","enrollment":520},{"nctId":"NCT03492385","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2018-04-03","conditions":"Healthy","enrollment":64},{"nctId":"NCT06671470","phase":"PHASE1","title":"A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-22","conditions":"Insomnia","enrollment":27},{"nctId":"NCT06667349","phase":"PHASE4","title":"TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2023-08-24","conditions":"STEMI - ST Elevation Myocardial Infarction, Stent Thrombosis, Antiplatelet Agents","enrollment":1727},{"nctId":"NCT06591390","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-02-09","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06561867","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-30","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06196047","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2023-12-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06202755","phase":"PHASE3","title":"Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-03-30","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT05980195","phase":"NA","title":"Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-07-16","conditions":"Carotid Stenosis, Cognitive Impairment, Hyperbaric Oxygen Therapy","enrollment":90},{"nctId":"NCT02016170","phase":"NA","title":"Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-03","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":82},{"nctId":"NCT05553613","phase":"PHASE3","title":"Ticagrelor Versus Clopidogrel in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-10-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT03161678","phase":"PHASE4","title":"CES1 Crossover Trial of Clopidogrel and Ticagrelor","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-08-22","conditions":"Myocardial Infarction, Thrombosis, Platelet Dysfunction","enrollment":111},{"nctId":"NCT03928353","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-04-16","conditions":"Healthy","enrollment":23},{"nctId":"NCT01556659","phase":"NA","title":"LV Thrombus After Acute AMI: A Randomized Controlled Trial","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2012-03","conditions":"Ventricular Thrombosis Mural Following Myocardial Infarction","enrollment":25},{"nctId":"NCT04122170","phase":"PHASE2","title":"Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-09-24","conditions":"Healthy","enrollment":207},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT05750758","phase":"NA","title":"Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty","status":"COMPLETED","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2023-02-20","conditions":"Acute Coronary Syndrome","enrollment":140},{"nctId":"NCT05223335","phase":"PHASE4","title":"Clopidogrel Monotherapy in Patients With High Bleeding Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-29","conditions":"Bleeding Complications","enrollment":98},{"nctId":"NCT06233266","phase":"PHASE1","title":"Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-06-18","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT05162131","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers","status":"TERMINATED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2021-12-25","conditions":"Healthy","enrollment":34},{"nctId":"NCT06120725","phase":"PHASE3","title":"Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2021-09-01","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT05825391","phase":"NA","title":"Guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-05-04","conditions":"Intracranial Aneurysm","enrollment":590},{"nctId":"NCT04057300","phase":"PHASE4","title":"Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2018-10-01","conditions":"Acute Coronary Syndrome","enrollment":1038},{"nctId":"NCT04738097","phase":"PHASE3","title":"Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2021-08-08","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":90},{"nctId":"NCT04702113","phase":"NA","title":"Evaluating Pharmacogenomic Variants for Cardiology Therapeutics","status":"COMPLETED","sponsor":"Cipherome, Inc.","startDate":"2020-12-03","conditions":"Thrombosis, Stent Thrombosis, Bleeding","enrollment":300},{"nctId":"NCT05903976","phase":"PHASE3","title":"De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","startDate":"2023-06-12","conditions":"Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT04237935","phase":"","title":"Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-22","conditions":"Antiplatelet","enrollment":27960},{"nctId":"NCT05858918","phase":"NA","title":"Ticagrelor vs. Clopidogrel in Post PCI Patients","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-10-01","conditions":"Stable Chronic Angina","enrollment":476},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT03234114","phase":"PHASE4","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-03","conditions":"Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)","enrollment":3746},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT03251859","phase":"PHASE3","title":"Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2017-08-11","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT03797651","phase":"NA","title":"Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-04-24","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":2850},{"nctId":"NCT04766437","phase":"PHASE2","title":"Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-02-19","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":75},{"nctId":"NCT03331484","phase":"PHASE3","title":"The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-11-01","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT03129867","phase":"","title":"ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2017-01-01","conditions":"Acute Coronary Syndrome","enrollment":480},{"nctId":"NCT03649711","phase":"PHASE3","title":"Chronic Kidney Disease (CKD) Platelet Study","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2018-11-01","conditions":"Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic","enrollment":76},{"nctId":"NCT02053909","phase":"PHASE4","title":"Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis","status":"COMPLETED","sponsor":"Boca Raton Regional Hospital","startDate":"2014-09","conditions":"Saphenous Vein Graft Disease","enrollment":250},{"nctId":"NCT04941196","phase":"PHASE1","title":"Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2020-10-16","conditions":"Healthy Individuals","enrollment":30},{"nctId":"NCT05474053","phase":"PHASE3","title":"Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-11-13","conditions":"Cardiovascular Diseases, Acute Coronary Syndrome","enrollment":29},{"nctId":"NCT03789916","phase":"PHASE3","title":"SAPT Versus DAPT in Incomplete Revascularization After CABG","status":"RECRUITING","sponsor":"Campus Bio-Medico University","startDate":"2019-01-02","conditions":"Coronary Artery Disease","enrollment":800},{"nctId":"NCT04739384","phase":"PHASE3","title":"Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS","status":"COMPLETED","sponsor":"Federico II University","startDate":"2021-04-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI","enrollment":50},{"nctId":"NCT02677545","phase":"PHASE2","title":"Ticagrelor Versus Clopidogrel in Carotid Artery Stenting","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-12","conditions":"Carotid Artery Stenosis","enrollment":210},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT02335099","phase":"PHASE1, PHASE2","title":"Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2014-12","conditions":"End Stage Renal Disease, Vascular Access Patency","enrollment":54},{"nctId":"NCT05373277","phase":"PHASE1","title":"KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2022-05-11","conditions":"Pharmacokinetics","enrollment":10},{"nctId":"NCT02325466","phase":"PHASE3","title":"Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-04","conditions":"Peripheral Artery Disease, Type 2 Diabetes","enrollment":70},{"nctId":"NCT05183178","phase":"PHASE4","title":"Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Acute Coronary Syndrome","enrollment":16000},{"nctId":"NCT01813435","phase":"PHASE3","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2013-07-01","conditions":"Coronary Artery Disease (CAD)","enrollment":15991},{"nctId":"NCT05247385","phase":"PHASE4","title":"Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2017-03-20","conditions":"Coronary Artery Disease","enrollment":87},{"nctId":"NCT02251249","phase":"PHASE4","title":"Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-12-08","conditions":"Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction","enrollment":23},{"nctId":"NCT02817789","phase":"PHASE3","title":"Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-05-09","conditions":"Aortic Valve Stenosis","enrollment":50},{"nctId":"NCT02539160","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-02","conditions":"Coronary Artery Disease, Diabetes Mellitus","enrollment":101},{"nctId":"NCT01742117","phase":"PHASE4","title":"Tailored Antiplatelet Therapy Following PCI","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-05","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Stenosis","enrollment":5276}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"RENAL FAILURE"},{"count":3,"reaction":"RHABDOMYOLYSIS"},{"count":2,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"BLOOD ALKALINE PHOSPHATASE ABNORMAL"},{"count":2,"reaction":"BLOOD CREATINE INCREASED"},{"count":2,"reaction":"BLOOD CREATINE PHOSPHOKINASE MB ABNORMAL"},{"count":2,"reaction":"CHROMATURIA"},{"count":2,"reaction":"DECREASED APPETITE"},{"count":2,"reaction":"DISTURBANCE IN ATTENTION"}],"crossReferences":{"chemblId":"CHEMBL398435"},"_approvalHistory":[],"publicationCount":173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ticagrelor 90","genericName":"Ticagrelor 90","companyName":"Sheffield Teaching Hospitals NHS Foundation Trust","companyId":"sheffield-teaching-hospitals-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:40:24.131888+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}